Evidence map›Paper›PMID 30244832›Full record

ArticleMolecular cell2018

A Loss of Epigenetic Control Can Promote Cell Death through Reversing the Balance of Pathways in a Signaling Network.

Kiran G Vanaja, Winston Timp, Andrew P Feinberg, Andre Levchenko

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Systems Biology of the Cancer Cell.Annual review of biomedical engineering · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Pten Regulates Cardiomyocyte Differentiation by Modulating Non-CG Methylation via Dnmt3.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kiran G VanajaYale Systems Biology Institute and Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine and Whiting School of Engineering, Baltimore, MD 21205, USA.
Winston TimpDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine and Whiting School of Engineering, Baltimore, MD 21205, USA.
Andrew P FeinbergDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine and Whiting School of Engineering, Baltimore, MD 21205, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address: afeinberg@jhu.edu.
Andre LevchenkoYale Systems Biology Institute and Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine and Whiting School of Engineering, Baltimore, MD 21205, USA. Electronic address: andre.levchenko@yale.edu.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Systems analysis of phenotypic switch in control of cancer invasionU54CA209992 · NCI · YALE UNIVERSITY · PI LEVCHENKO, ANDRE · 2016 to 2021
$10.1M
GENOMIC IMPRINTING IN CANCERR01CA065145 · NCI · JOHNS HOPKINS UNIVERSITY · PI LEVCHENKO, ANDRE · 1994 to 2011
$5.8M
MOLECULAR PATHOLOGY OF WILMS TUMOR RELATED GENES 11PR01CA054358 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDREW P. FEINBERG · 1991 to 2026
$5.5M
Information tranfer in NF-kappaB and MAPK pathwaysR01GM072024 · NIGMS · YALE UNIVERSITY · PI LEVCHENKO, ANDRE · 2004 to 2019
$3.9M
NCI NIH HHS R01 CA054358NCI NIH HHS R01 CA065145NCI NIH HHS U54 CA209992NIGMS NIH HHS R01 GM072024
6 · The paper itself

Abstract

Epigenetic control of regulatory networks is only partially understood. Expression of Insulin-like growth factor-II (IGF2) is controlled by genomic imprinting, mediated by silencing of the maternal allele. Loss of imprinting of IGF2 (LOI) is linked to intestinal and colorectal cancers, causally in murine models and epidemiologically in humans. However, the molecular underpinnings of the LOI phenotype are not clear. Surprisingly, in LOI cells, we find a reversal of the relative activities of two canonical signaling pathways triggered by IGF2, causing further rebalancing between pro- and anti-apoptotic signaling. A predictive mathematical model shows that this network rebalancing quantitatively accounts for the effect of receptor tyrosine kinase inhibition in both WT and LOI cells. This mechanism also quantitatively explains both the stable LOI phenotype and the therapeutic window for selective killing of LOI cells, and thus prevention of epigenetically controlled cancers. These findings suggest a framework for understanding epigenetically modified cell signaling.

Indexed as

AnimalsApoptosisCell Line, TumorColorectal NeoplasmsEpigenesis, GeneticGene Expression Regulation, NeoplasticGenomic ImprintingHumansInsulin-Like Growth Factor IIMicePhenotypeSignal TransductionIGF2 protein, humanInsulin-Like Growth Factor IIAKTapoptosiscomputational modeldeath planeepigeneticsERKimprintingkinase signalingnetwork rewiringoncogene addiction

Identifiers

PMID30244832
PMCPMC6219618
OpenAlexW2891796000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.